Capital Research Global Investors Sells 34,749 Shares of AbbVie Inc. $ABBV

Key Points

• Capital Research Global Investors slightly trimmed its position in AbbVie, selling 34,749 shares in Q3 to hold 25,230,830 shares (about 1.43% of AbbVie) valued at $5.84 billion; AbbVie represents 1.1% of the firm's portfolio and is its 20th-largest holding.
• AbbVie beat Q results (EPS $2.71 vs. $2.65; revenue $16.62B, +10% YoY), set FY2026 EPS guidance of 14.370–14.570, and declared a quarterly dividend of $1.73 ($6.92 annual, ~3.0% yield).
• Pipeline and sentiment are mixed: positive trial readouts for ABBV‑295 (obesity) and SKYRIZI (Crohn’s) and strong broker support boost the outlook, but a recent ICER review, mixed market reaction and notable insider sales have tempered enthusiasm; consensus rating is a Moderate Buy with an average target of $253.15.

Capital Research Global Investors lessened its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 0.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,230,830 shares of the company's stock after selling 34,749 shares during the quarter. AbbVie accounts for 1.1% of Capital Research Global Investors' investment portfolio, making the stock its 20th largest position. Capital Research Global Investors owned approximately 1.43% of AbbVie worth $5,841,882,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in ABBV. Capital International Inc. CA grew its position in shares of AbbVie by 39.4% during the 3rd quarter. Capital International Inc. CA now owns 240,358 shares of the company's stock valued at $55,652,000 after acquiring an additional 67,912 shares during the period. Bank of Montreal Can increased its position in AbbVie by 6.4% in the third quarter. Bank of Montreal Can now owns 2,975,374 shares of the company's stock worth $688,918,000 after buying an additional 177,720 shares during the last quarter. Legal & General Group Plc raised its stake in shares of AbbVie by 4.3% in the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company's stock valued at $2,779,426,000 after buying an additional 493,420 shares during the period. Pinkerton Wealth LLC raised its stake in shares of AbbVie by 7.5% in the third quarter. Pinkerton Wealth LLC now owns 29,386 shares of the company's stock valued at $6,804,000 after buying an additional 2,051 shares during the period. Finally, Sienna Gestion lifted its position in shares of AbbVie by 712.1% during the 3rd quarter. Sienna Gestion now owns 40,255 shares of the company's stock valued at $8,498,000 after buying an additional 35,298 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Down 1.0%

NYSE:ABBV opened at $227.75 on Tuesday. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The stock has a market cap of $402.70 billion, a P/E ratio of 96.50, a PEG ratio of 0.80 and a beta of 0.34. The business's 50-day moving average price is $224.66 and its two-hundred day moving average price is $224.33.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company's revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. AbbVie's payout ratio is currently 293.22%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ABBV. William Blair reissued an "outperform" rating on shares of AbbVie in a report on Monday. Sanford C. Bernstein reiterated a "market perform" rating on shares of AbbVie in a research report on Thursday, February 5th. Morgan Stanley lifted their target price on shares of AbbVie from $269.00 to $270.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. The Goldman Sachs Group reiterated a "neutral" rating and set a $223.00 price objective on shares of AbbVie in a research note on Wednesday, January 28th. Finally, Barclays started coverage on AbbVie in a report on Thursday, February 19th. They set an "overweight" rating and a $275.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, AbbVie presently has an average rating of "Moderate Buy" and an average price target of $253.15.

Insider Activity at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the firm's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the firm's stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.08% of the company's stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Phase 1 ABBV‑295 (long‑acting amylin analog) topline results showed clinically meaningful weight loss (~7.8%–9.8% at ~12–13 weeks) with a favorable tolerability profile, supporting continued development of a non‑incretin obesity treatment — a potential new growth driver outside AbbVie’s GI/immunology franchise. AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
• Positive Sentiment: Positive topline Phase 3 AFFIRM results for SKYRIZI (risankizumab) in Crohn’s disease increase the likelihood of label expansion and incremental revenue from AbbVie’s immunology franchise. This helps the company’s growth outlook beyond its legacy products. AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease
• Positive Sentiment: Major broker support remains — J.P. Morgan has stuck with a buy rating, which can help stabilize sentiment amid pipeline news and support investor demand. J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
• Neutral Sentiment: Analyst and retail attention is rising (momentum screens and coverage), which can amplify moves but doesn’t guarantee directional conviction; investors should watch follow‑on data and commercialization signals. Here's Why AbbVie (ABBV) is a Strong Momentum Stock
• Neutral Sentiment: Recent trial updates (Crohn’s + ABBV‑295) are being used to re‑price AbbVie’s mid‑term valuation; they add context but require regulatory, commercial and longer‑term outcome confirmation. AbbVie Trial Updates Add Context To Valuation And Growth Outlook
• Negative Sentiment: ICER will review AbbVie’s Parkinson’s disease drug, introducing potential pricing and reimbursement scrutiny that could limit commercial upside or pressure expected margins for that program. ICER to review AbbVie’s Parkinson’s disease drug
• Negative Sentiment: Market reaction has been mixed — reports note shares fell after the early obesity data, suggesting investors may be taking profits or weighing valuation against what remains early‑stage evidence. AbbVie's Early Obesity Drug Data Shows Up To 10% Weight Loss
• Negative Sentiment: An AbbVie SVP sold about $1.22M of stock; insider sales can be read as a near‑term negative signal even if not uncommon at large companies. AbbVie NYSE: ABBV SVP Sells $1,221,518.80 in Stock

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.